Cohort-specific validation by immunohistochemistry on well-annotated tumor microarray with survival endpoints will be necessary to establish prognostic value and to support PLXNA4 as a PCa biomarker. This evidence concerns the gene PLXNA4 and posterior cortical atrophy.